Download PDF
Viszeralchirurgie 2002; 37(2): 150-156
DOI: 10.1055/s-2002-25171
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Strahlentherapie beim Mammakarzinom:
Was ist Standard? Was ist Zukunft?

Radiotherapy in breast cancer. What is standard? What is future?Th.  Kuhnt, J.  Dunst
  • 1Klinik für Strahlentherapie, Martin-Luther-Universität Halle-Wittenberg
Further Information

Publication History

Publication Date:
18 April 2002 (online)

    Permissions and Reprints

Zusammenfassung

Die Strahlentherapie ist seit vielen Jahren ein fester Bestandteil in der Therapie des Mammakarzinoms. Der Kernpunkt der kontroversen wissenschaftlichen Debatte der letzten Jahre betraf die Frage, ob neben der unstrittigen Verbesserung der lokalen Kontrolle auch ein positiver Effekt auf das Gesamtüberleben resultiert. Diese Frage kann zwischenzeitlich als weitgehend geklärt angesehen werden. Mehrere Studien der letzten Jahren bestätigen eindeutig, dass durch die Verhinderung von lokalen Rezidiven auch das Risiko von Fernmetastasen verringert und die Überlebensrate verbessert werden kann. Diese Daten haben weltweit zu einer Neubewertung der adjuvanten Strahlentherapie geführt. Der folgende Artikel fasst die wesentlichen Studienergebnisse und Empfehlungen für die etablierten Indikationen zusammen.

Abstract

For many years radiotherapy has been an integral part of the treatment of breast cancer. The focal point of the controversial scientific debate during the past few years was whether besides the undisputed improvement in local control there would also be a positive effect on overall survival. This question can now be considered as largely settled. Several studies conducted during the last few years definitely confirm that the prevention of local relapses can also reduce the risk of distant metastases and enhance the survival rate. These data led to a world-wide re-evaluation of adjuvant radiotherapy. The following article summarizes the essential results of the studies and the recommendations for the established indications.

Schlüsselwörter

Mammakarzinom - Radiotherapie - Leitlinien - Nebenwirkungen

Key words

Breast cancer - radiotherapy - toxicity - guidelines

Literatur

  • 1 Frykberg E R, Bland K I. Overview of the biology and management of ductal carcinoma in situ of the breast.  Cancer. 1994;  74 350-361
    PubMedGoogle Scholar
  • 2 Fisher B, Costantino J, Redmond C. et al . Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.  N Engl J Med.. 1993;  328 1581-1586
    CrossrefPubMedGoogle Scholar
  • 3 Fowble B, Hanlon A L, Fein D A. et al . Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS).  Int J Radiat Oncol Biol Phys.. 1997;  38 949-957
    CrossrefPubMedGoogle Scholar
  • 4 Skinner K A, Silverstein M J. The management of ductal carcinoma in situ of the breast.  Endocr Relat Cancer.. 2001;  8 33-45
    CrossrefPubMedGoogle Scholar
  • 5 Solin L J, McCormick B, Recht A. et al . Mammographically Detected, Clinically Occult Ductal Carcinoma. In Situ Treated With Breast-Conserving Surgery and Definitive Breast Irradiation.  Cancer J Sci Am. 1996;  2 158
    PubMedGoogle Scholar
  • 6 Fischer B, Dignam J, Wolmark N. et al . Tamoxifen in the treatment of intraductal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.  Lancet. 1999;  353 1993-2000
    CrossrefPubMedGoogle Scholar
  • 7 Morris A D, Morris R D, Wilson J F. et al . Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival.  Cancer J Sci Am. 1997;  3 6-12
    PubMedGoogle Scholar
  • 8 van Dongen J A, Voogd A C, Fentiman I S. et al . Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial.  J Natl Cancer Inst. 2000;  92 1143-1150
    CrossrefPubMedGoogle Scholar
  • 9 Veronesi U, Luini A, Del Vecchio M. et al . Radiotherapy after breast-preserving surgery in women with localized cancer of the breast.  N Engl J. Med.1993;  328 158715-91
    PubMedGoogle Scholar
  • 10 Fisher B, Wickerham D L, Deutsch M, Anderson S, Redmond C, Fisher E R. Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings.  Semin Surg Oncol.. 1992;  8 153-160
    PubMedGoogle Scholar
  • 11 Clark R M, McCulloch P B, Levine M N. et al . Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer.  J Natl Cancer Inst.. 1992;  84 683-689
    PubMedGoogle Scholar
  • 12 Liljegren G, Holmberg L, Bergh J. et al . 10-Year Results After Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: A Randomized Trial.  J Clin Oncol. 1999;  17 2326
    PubMedGoogle Scholar
  • 13 Forrest A P, Stewart H J, Everington D. et al . Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.  Lancet. 1996;  348 708-713
    CrossrefPubMedGoogle Scholar
  • 14 Bartelink H, Horiot J-C, Poortmans P. et al . The European Organization for Research and Treatment. Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation.  N Engl J Med. 2001;  345 1378-1387
    CrossrefPubMedGoogle Scholar
  • 15 Fisher B, Anderson S, Redmond C K. et al . Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.  N Engl J Med. 1995;  333 1456-1461
    CrossrefPubMedGoogle Scholar
  • 16 Voogd A C, Nielsen M, Peterse J L. et al . Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials.  J Clin Oncol. 2001;  19 1688-1697
    PubMedGoogle Scholar
  • 17 Park C C, Mitsumori M, Nixon A. et al . Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence.  J Clin Oncol.. 2000;  18 1668-1675
    PubMedGoogle Scholar
  • 18 Schnitt S J, Abner A, Gelman R. et al . The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy.  Cancer.. 1994;  74 1746-1751
    PubMedGoogle Scholar
  • 19 Bartelink H. et al . Impact of a boost dose on local control and cosmesis in patients with early breast cancer: the EORTC “boost versus no boost”-trial.  Int J Radiat Oncol Biol Phys. 2000;  48 111
    PubMedGoogle Scholar
  • 20 Romestaing P, Lehingue Y, Delaunay D, Carrie C. Role of a 10 Gy boost in the conservation treatment of early breast cancer: results of a randomized clinical trial in Lyon, France.  Int J Radiat Oncol Biol Phys. 2001;  51 3-4
    PubMedGoogle Scholar
  • 21 Urbau J A, Marjani M A. Significance of internal mammary lymph node metastases in breast cancer.  Am J Roentgenol Radium Ther Nucl Med. 1971;  111 130-136
    PubMedGoogle Scholar
  • 22 Recht A, Come S E, Henderson I C. et al . The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.  N Engl J Med. 1996;  334 1356-1361
    CrossrefPubMedGoogle Scholar
  • 23 Bellon J R, Come S E, Gelman R S. et al . Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: updated results of a prospective randomized trial.  Int J Radiat Oncol Biol Phys. 2001;  51 2-3
    PubMedGoogle Scholar
  • 24 Hardenbergh P H, Recht A, Gollamudi S. et al . Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer.  Int J Radiat Oncol Biol. Phys.1999;  45 69-72
    PubMedGoogle Scholar
  • 25 Jones G W. Radiotherapy reduces death from and recurrence of breast cancer but increases death from other causes.  Evid Based Med . 2001;  6 53
    PubMedGoogle Scholar
  • 26 Sauer R, Schulz K D, Hellriegel K P. Strahlentherapie nach Mastektomie: interdisziplinärer Konsensus beendet Kontroverse.  Strahlenther Onkol. 2001;  177 1-9
    PubMedGoogle Scholar
  • 27 Harris J R, Halpin-Murphy P, McNeese M. et al . Consensus statement of postmastectomy radiation therapy.  Int J Radiat Oncol Biol Phys. 1999;  44 989-990
    PubMedGoogle Scholar
  • 28 Recht A. et al . Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology.  J Clin Oncol. 2001;  19 1539-1569
    CrossrefPubMedGoogle Scholar
  • 29 Overgaard M, Jensen M B, Overgaard J. et al . Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.  Lancet. 1999;  353 1641-1648
    CrossrefPubMedGoogle Scholar
  • 30 Overgaard M, Hansen P S, Overgaard J. et al . Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.  N Engl J Med. 1997;  337 949-955
    CrossrefPubMedGoogle Scholar
  • 31 Ragaz J, Jackson S M, Le N, Plenderleith I H. et al . Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.  N Engl J Med. 1997;  337 956-962
    CrossrefPubMedGoogle Scholar
  • 32 van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link.  Radiother Oncol. 2000;  55 263-272
    CrossrefPubMedGoogle Scholar
  • 33 Whelan T J, Julian J, Wright J, Jadad A R, Levine M L. Does locoregional irradiation improve survival in breast cancer ? A meta-analysis.  J Clin Oncol. 2000;  18 1220-1229
    PubMedGoogle Scholar
  • 34 Urban J A, Marjani M A. Significance of internal mammary lymph node metastases in breast cancer.  Am J Roentgenol Radium Ther Nucl Med. 1971;  111 130-136
    PubMedGoogle Scholar
  • 35 Thoms W W, McNeese M D, Fletcher G H. et al . Multimodal treatment for inflammatory breast cancer.  Int J Radiat Oncol Biol Phys. 1989;  17 739-745
    PubMedGoogle Scholar
  • 36 Jacquillat C, Weil M, Baillet F. et al . Results of neoadjuvant chemotherapy and radiation therapy in the breast conserving treatment of 250 patients with all stages of infiltrative breast cancer.  Cancer. 1990;  66 119-129
    PubMedGoogle Scholar
  • 37 Boyages L, Langlands A O. The efficacy of combined chemotherapy and radiotherapy in advanced non-metastatic breast cancer.  Int J Radiat Oncol Biol Phys. 1988;  14 71-78
    PubMedGoogle Scholar
  • 38 Seegenschmiedt M H. Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives.  Strahlenther Onkol. 1998;  174 25-29
    CrossrefPubMedGoogle Scholar
  • 39 Paszat L F, Mackillop W J, Groome P A, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.  J Clin Oncol. 1998;  16 2625-2631
    PubMedGoogle Scholar
  • 40 Pierce L J. Treatment Guidelines and Techniques in Delivery of Postmastectomy Radiotherapy in Management of Operable Breast Cancer.  J Natl Cancer I Monographs. 2001;  117 124
    PubMedGoogle Scholar
  • 41 Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk.  Int J Radiat Oncol Biol Phys. 2001;  51 679-690
    CrossrefPubMedGoogle Scholar
  • 42 Obedian E, Fischer D B, Haffty B G. Second Malignancies After Treatment of Early-Stage Breast Cancer: Lumpectomy and Radiation Therapy Versus Mastectomy.  J Clin Oncol. 2000;  18 2406-2412
    PubMedGoogle Scholar
  • 43 Dunst J, Steil B, Furch S. et al . Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy.  Strahlenther Onkol. 2001;  177 504-510
    CrossrefPubMedGoogle Scholar
  • 44 EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group . Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM).  Eur J Cancer. 1999;  35 32-38
    CrossrefPubMedGoogle Scholar
  • 45 Aberizk W J, Silver B, Henderson I C, Cady B, Harris J R. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy.  Cancer. 1986;  58 1214-1218
    CrossrefPubMedGoogle Scholar
  • 46 Freedman G M, Fowble B L. Local recurrence after mastectomy or breast-conserving surgery and radiation.  Oncology. 2000;  14 1561-1581
    PubMedGoogle Scholar
  • 47 Toonkel L M, Fix I, Jacobson L H, Wallach C B. The significance of local recurrence of carcinoma of the breast.  Int J Radiat Oncol Biol Phys. 1983;  9 33-39
    PubMedGoogle Scholar
  • 48 Plasswilm L, Seegenschmiedt M H, Ganssauge F, Sauer R. Simultaneous radiochemotherapy for recurrent and metastatic breast carcinoma: evaluation of two treatment concepts.  Am J Clin Oncol. 1996;  19 403-407
    CrossrefPubMedGoogle Scholar
  • 49 Renner H, van Kampen M. Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor.  Strahlenther Onkol. 1994;  170 441-452
    PubMedGoogle Scholar

1 Das lobuläre In-situ-Karzinom (LCIS) gilt nicht als obligate Präkanzerose, sondern lediglich als Risikofaktor für das Entstehen anderer invasiver Karzinome. Die Therapie der Wahl ist die Tumorektomie mit konsequenter Nachbeobachtung. Eine Nachbestrahlung ist beim LCIS nicht indiziert.

Prof. Dr. Jürgen Dunst

Direktor der Universitätsstrahlenklinik der Martin-Luther-Universität
Halle-Wittenberg

Dryanderstraße 4

06097 Halle/Saale

Phone: 0345-5574310

Fax: 0345-5574333

Email: juergen.dunst@medizin.uni-halle.de